Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Powders × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 4 Urogenital Neoplasms 2 Lung Neoplasms 2 Leukemia 2 Stomach Neoplasms 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Recurrence 1 Ovarian Neoplasms 1 Metabolic Diseases 1 Leukemia, Myeloid, Acute 1 Kidney Neoplasms 1 Keratosis, Actinic 1 Genital Neoplasms, Male 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Cachexia 1

Interventions

Cyclophosphamide 133 Dexamethasone 107 Rituximab 70 fludarabine 65 Lenalidomide 59 Cytarabine 59 Gemcitabine 54 fludarabine phosphate 49 Bortezomib 48 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 42 Cisplatin 41 pomalidomide 39 Peripheral Blood Stem Cell Transplantation 38 Filgrastim 37 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Busulfan 31 Calcium Dobesilate 29 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Nivolumab 25 Mycophenolic Acid 25 Temozolomide 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00989261 2019-12-11

ACE

Daiichi Sankyo

Phase 2 Completed

333 enrolled 23 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡